Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Antengene Corporation Limited
  6. News
  7. Summary
    6996   KYG039571008

ANTENGENE CORPORATION LIMITED

(6996)
  Report
Delayed Hong Kong Stock Exchange  -  04:08:08 2023-03-24 am EDT
3.040 HKD   -1.30%
03/21Antengene Announces Five Upcoming Presentations at the 2023 American Association for Cancer Research Annual Meeting
AQ
03/13Antengene Obtains China Approval for Phase I Study of Tumor Treatment
MT
03/13Antengene Corporation Limited Announces Approval for the Phase I Clinch Trial of ATG-022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Antengene Corporation Limited Announces Executive Changes

06/18/2021 | 01:29am EDT
share with twitter
share with LinkedIn
share with facebook

Antengene Corporation Limited announced that Mr. Yiteng Liu and Mr. Zhen Li has retired as an executive Director and a non-executive Director, respectively, at the conclusion of the AGM. Dr. Kevin Patrick Lynch and Mr. Donald Andrew Lung have been elected as executive Directors at the AGM with effect from June 18, 2021.


© S&P Capital IQ 2021
All news about ANTENGENE CORPORATION LIMITED
03/21Antengene Announces Five Upcoming Presentations at the 2023 American Association for Ca..
AQ
03/13Antengene Obtains China Approval for Phase I Study of Tumor Treatment
MT
03/13Antengene Corporation Limited Announces Approval for the Phase I Clinch Trial of ATG-02..
CI
03/13Antengene Says It Has No Business Relationship with Silicon Valley Bank
MT
03/12Over a dozen Chinese-based firms say they have minimal exposure to SVB
RE
02/02Australian Regulator Approve Antengene's Phase I Trial for Tumor Treatment; Shares Clim..
MT
01/05Antengene Signs Assignment Deal with Calithera to Acquire Rights on Cancer Tumor Drug; ..
MT
01/03Antengene to Present at the 41st Annual J.P. Morgan Healthcare Conference
PR
2022Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-037 (CD7..
AQ
2022Merck, Antengene Partner to Assess ATG-037 Combined With Keytruda in Solid Tumor Phase ..
MT
More news
Financials
Sales 2022 181 M 26,6 M 26,6 M
Net income 2022 -537 M -78,8 M -78,8 M
Net Debt 2022 14,8 M 2,17 M 2,17 M
P/E ratio 2022 -3,10x
Yield 2022 -
Capitalization 1 782 M 261 M 261 M
EV / Sales 2022 9,91x
EV / Sales 2023 3,48x
Nbr of Employees 383
Free-Float 64,4%
Chart ANTENGENE CORPORATION LIMITED
Duration : Period :
Antengene Corporation Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ANTENGENE CORPORATION LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 2,64 CNY
Average target price 8,62 CNY
Spread / Average Target 226%
EPS Revisions
Managers and Directors
Jian Ming Mei Chairman & Chief Executive Officer
Donald Andrew Lung Chief Financial Officer & Executive Director
Bo Shan Chief Scientific Officer
Xiao-Jing Zhang Chief Medical Officer
Yiteng Liu Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
ANTENGENE CORPORATION LIMITED-40.19%265
REGENERON PHARMACEUTICALS, INC.11.18%85 611
VERTEX PHARMACEUTICALS5.53%78 349
WUXI APPTEC CO., LTD.-0.89%34 400
BIONTECH SE-13.87%31 444
GENMAB A/S-13.29%24 332
MarketScreener: Created by Investors for Investors!
100% Free Registration
fermer